Connection

Angelo Avogaro to Diabetes Mellitus, Type 2

Back to Details
This is a "connection" page, showing publications Angelo Avogaro has written about Diabetes Mellitus, Type 2.
Angelo Avogaro
Connection Strength
3.432
Diabetes Mellitus, Type 2
  1. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. Diabetes Obes Metab. 2020 10; 22(10):1946-1950.
    View in: PubMed
    Score: 0.189
  2. Angiogenic Abnormalities in Diabetes Mellitus: Mechanistic and Clinical Aspects. J Clin Endocrinol Metab. 2019 11 01; 104(11):5431-5444.
    View in: PubMed
    Score: 0.181
  3. One-year caloric restriction and 12-week exercise training intervention in obese adults with type 2 diabetes: emphasis on metabolic control and resting metabolic rate. J Endocrinol Invest. 2019 Dec; 42(12):1497-1507.
    View in: PubMed
    Score: 0.178
  4. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. J Am Heart Assoc. 2019 07 16; 8(14):e012244.
    View in: PubMed
    Score: 0.177
  5. The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors. Br J Clin Pharmacol. 2018 08; 84(8):1686-1695.
    View in: PubMed
    Score: 0.164
  6. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. Diabetes Obes Metab. 2018 Jun; 20(6):1367-1368.
    View in: PubMed
    Score: 0.161
  7. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. Diabetes Metab Res Rev. 2018 05; 34(4):e2981.
    View in: PubMed
    Score: 0.161
  8. p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications. Cardiovasc Diabetol. 2018 01 17; 17(1):16.
    View in: PubMed
    Score: 0.160
  9. Keeping the right track in the treatment of patients with type 2 diabetes. Eur J Heart Fail. 2018 01; 20(1):52-54.
    View in: PubMed
    Score: 0.159
  10. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018 03; 20(3):740-744.
    View in: PubMed
    Score: 0.158
  11. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017 09; 5(9):680-681.
    View in: PubMed
    Score: 0.154
  12. Re: "Plasminogen Activator Inhibitor-1 and Pericardial Fat in Individuals with Type 2 Diabetes Mellitus" by Bayomi et al. (Metab Syndr Relat Disord 2017;15:269-275). Metab Syndr Relat Disord. 2017 08; 15(6):266-268.
    View in: PubMed
    Score: 0.153
  13. A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol. 2017 Jul; 10(7):763-772.
    View in: PubMed
    Score: 0.152
  14. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017 04 04; 16(1):42.
    View in: PubMed
    Score: 0.151
  15. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes. Expert Opin Pharmacother. 2017 Apr; 18(5):517-527.
    View in: PubMed
    Score: 0.151
  16. The role of point-of-care 3-hydroxybutyrate testing in patients with type 2 diabetes undergoing coronary angiography. J Endocrinol Invest. 2017 Jun; 40(6):627-634.
    View in: PubMed
    Score: 0.150
  17. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes. J Clin Endocrinol Metab. 2016 Feb; 101(2):748-56.
    View in: PubMed
    Score: 0.138
  18. Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2019; 7(1):e000725.
    View in: PubMed
    Score: 0.045
  19. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. Diabetes Obes Metab. 2019 11; 21(11):2542-2552.
    View in: PubMed
    Score: 0.045
  20. Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2019 Sep; 56(9):1051-1060.
    View in: PubMed
    Score: 0.044
  21. Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetol. 2019 Jun; 56(6):605-617.
    View in: PubMed
    Score: 0.043
  22. Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2018 10 01; 103(10):3773-3782.
    View in: PubMed
    Score: 0.042
  23. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes Obes Metab. 2019 02; 21(2):252-260.
    View in: PubMed
    Score: 0.042
  24. Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study. Acta Diabetol. 2018 Nov; 55(11):1121-1129.
    View in: PubMed
    Score: 0.042
  25. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes Obes Metab. 2018 07; 20(7):1781-1786.
    View in: PubMed
    Score: 0.040
  26. The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetol. 2018 Jun; 55(6):593-601.
    View in: PubMed
    Score: 0.040
  27. Insulin treatment in patients with diabetes and heart failure: defendant on the stand. Eur J Heart Fail. 2018 05; 20(5):896-897.
    View in: PubMed
    Score: 0.040
  28. Assessment of hypoglycaemia during basal insulin therapy: Temporal distribution and risk of events using a predefined or an expanded definition of nocturnal events. Diabetes Metab. 2018 Sep; 44(4):333-340.
    View in: PubMed
    Score: 0.040
  29. Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis. 2017 Dec; 27(12):1089-1097.
    View in: PubMed
    Score: 0.039
  30. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab. 2018 01; 20(1):25-33.
    View in: PubMed
    Score: 0.038
  31. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry. Diabetes Obes Metab. 2017 10; 19(10):1416-1424.
    View in: PubMed
    Score: 0.038
  32. A decade-long telemedicine screening program for diabetic retinopathy in the north-east of Italy. J Diabetes Complications. 2017 Aug; 31(8):1348-1353.
    View in: PubMed
    Score: 0.038
  33. Silent coronary heart disease in patients with type 2 diabetes: application of a screening approach in a follow-up study. J Diabetes Complications. 2017 Jun; 31(6):952-957.
    View in: PubMed
    Score: 0.038
  34. Ketone body metabolism in NIDDM. Effect of sulfonylurea treatment. Diabetes. 1992 Aug; 41(8):968-74.
    View in: PubMed
    Score: 0.027
  35. Mechanisms linking empagliflozin to cardiovascular and renal protection. Int J Cardiol. 2017 Aug 15; 241:450-456.
    View in: PubMed
    Score: 0.009
  36. Integrated kinematics-kinetics-plantar pressure data analysis: a useful tool for characterizing diabetic foot biomechanics. Gait Posture. 2012 May; 36(1):20-6.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.